Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Sunitinib
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Clinical Benefit
75%
Clinical Data
25%
Progression-free Survival
25%
Cox Regression Analysis
25%
Pharmacodynamics
25%
Single nucleotide Polymorphism
25%
Odds Ratio
25%
Logistic Regression Analysis
25%
Multivariable
25%
Tumor Reduction
25%
Vascular Endothelial Growth Factor
25%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
25%
Pazopanib
25%
Clinical Progression
25%
Tumor Downsizing
25%
95% Confidence Interval
25%
Sunitinib Treatment
25%
Allele Carriers
25%
Variant Carriers
25%
Soluble VEGFR2
25%
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor
25%
Pharmacology, Toxicology and Pharmaceutical Science
Sunitinib
100%
Kidney Metastasis
100%
Neoplasm
40%
Vasculotropin Receptor
40%
Biological Marker
20%
Pharmacodynamics
20%
Protein Tyrosine Kinase Inhibitor
20%
Progression Free Survival
20%
Protein Tyrosine Kinase
20%
Pazopanib
20%
Renal Cell Carcinoma
20%
Immunology and Microbiology
Sunitinib
100%
Vasculotropin
40%
Allele
20%
Wild Type
20%
Single Nucleotide Polymorphism
20%
Progression Free Survival
20%
Tumor Volume
20%
Pharmacodynamics
20%
Pazopanib
20%
Tyrosine
20%
Phosphotransferase
20%
Kinase
20%
Biochemistry, Genetics and Molecular Biology
Sunitinib
100%
VEGF Receptors
40%
Allele
20%
Progression Free Survival
20%
Wild Type
20%
Single-Nucleotide Polymorphism
20%
Tumor Volume
20%
Pharmacodynamics
20%
Receptor Tyrosine Kinase Inhibitors
20%
Pazopanib
20%